Head to head
Metformin against Empagliflozin
Both are oral, both are prescribed in type 2 diabetes, and only one of them has randomised outcome trials reporting fewer deaths. Empagliflozin's ageing case, by contrast, rests on a single laboratory mouse study, while metformin's rests on decades of observational data that randomised work has not confirmed.
Column A
MetforminMetformin hydrochloride (biguanide)
The most discussed drug in longevity, with enormous human safety data and a geroscience record that is consistently null. It also blunts the muscle and fitness gains from training.
Column B
EmpagliflozinEmpagliflozin (sodium-glucose cotransporter 2 inhibitor)
Four randomised outcome trials in more than 23,000 people, including a 32 percent relative reduction in all-cause death in EMPA-REG OUTCOME. The entire ageing case is one single-laboratory mouse study reporting 5.9 percent longer median survival in males, and the Interventions Testing Program has never tested this drug.
Side by side, on the facts we can check
| Attribute | Metformin | Empagliflozin |
|---|---|---|
| Category | Longevity | Metabolic |
| FDA status | FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity. | FDA approved for type 2 diabetes, for reducing cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, for heart failure across the ejection fraction range, and for chronic kidney disease. Not approved for ageing, longevity or healthspan. |
| Half-life | 4 to 9 hours (plasma), longer in erythrocytes | About 12 hours. |
| Molecular weight | 129.2 Da (165.6 Da as hydrochloride) | 450.9 Da |
| Mechanism | Inhibits mitochondrial complex I and activates AMPK, reducing hepatic glucose output and improving insulin sensitivity. The AMPK account is incomplete and the relative contribution of complex I inhibition, mitochondrial glycerophosphate dehydrogenase and gut-mediated effects is actively disputed between research groups. | Selectively inhibits sodium-glucose cotransporter 2 in the proximal tubule, so filtered glucose is excreted rather than reabsorbed. The cardiorenal benefit is larger and faster than glucose lowering alone explains and is not fully accounted for. Candidate contributions include reduced plasma volume and preload, restored tubuloglomerular feedback and lower intraglomerular pressure, a shift toward ketone utilisation by the myocardium, and reduced cardiac sodium-hydrogen exchange. The mouse healthspan work adds AMPK and SIRT1 signalling, short-chain fatty acid production and gut microbial composition to that list, which is a different level of evidence from the outcome trials. |
| Human studies cited | 3 | 4 |
| Legal status, US | Prescription only; approved for type 2 diabetes | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Metformin and Empagliflozin?
Metformin: The most discussed drug in longevity, with enormous human safety data and a geroscience record that is consistently null. It also blunts the muscle and fitness gains from training. Empagliflozin: Four randomised outcome trials in more than 23,000 people, including a 32 percent relative reduction in all-cause death in EMPA-REG OUTCOME. The entire ageing case is one single-laboratory mouse study reporting 5.9 percent longer median survival in males, and the Interventions Testing Program has never tested this drug.
Which has stronger research evidence, Metformin or Empagliflozin?
This database does not grade compounds. It counts what was run in people: 3 of the 4 studies cited on the Metformin profile were human work, against 4 of 6 for Empagliflozin. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Metformin and Empagliflozin FDA-approved?
Metformin: FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity.. Empagliflozin: FDA approved for type 2 diabetes, for reducing cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, for heart failure across the ejection fraction range, and for chronic kidney disease. Not approved for ageing, longevity or healthspan..
Related posts
Blog articles that cover Metformin or Empagliflozin, newest first.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.